Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

Tharimmune (THAR) Shares Skyrocket On Promising Opioid Countermeasure Data

Shares of Tharimmune Inc (NASDAQ:THAR) are surging Thursday afternoon after the company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104.

Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

5 Healthcare Stocks On Fire This Week

Five healthcare stocks have emerged as standout performers, posting remarkable week-on-week momentum gains according to the latest Benzinga Edge Ranking report.

Benzinga

Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Shares of Nordson Corporation (NASDAQ:NDSN) rose sharply in pre-market trading after the company reported better-than-expected third-quarter results.

Benzinga

Tharimmune Rockets 42% After Hours — Adding To Stunning 206% Daytime Rally: What's Going On?

Tharimmune Inc. (NASDAQ:THAR) jumped 42.06% to $5.10 in after-hours trading on Wednesday following positive pharmacokinetic simulation results for its lead drug candidate TH104, designed to prevent respiratory depression from fentanyl exposure.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Who Is Anna Bouyzk? Woman Attacks Neighbour with Anti-Semitic Slurs and Said His Dead Daughter Deserved To Die

Anna Bouyzk, wife of biotech entrepreneur Mark Bouzyk, is accused of hurling anti-Semitic slurs at her neighbour David Lubin, whose daughter, a 20-year-old IDF soldier, was killed in Jerusalem.

International Business Times UK

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.

Benzinga

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Benzinga

NovaBay Pharmaceuticals Soars 66% In Pre-Market On $6 Million Investment Deal, CEO Appointment

NovaBay Pharmaceuticals Inc. (NYSE:NBY) surged 66.57% in pre-market trading to $1 on Wednesday, following the announcement of major investment and leadership changes that could prevent the company’s liquidation.

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Thermo Fisher Positioned As Biopharma's Partner Of Choice

Could Thermo Fisher Scientific Inc. (NYSE:TMO) be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential. William Blair initiated coverage on Tuesday on Thermo Fisher Scientific, citing a strong…

Benzinga

PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s (NASDAQ:PTCT) New Drug Application (NDA) for vatiquinone for Friedreich’s ataxia.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications.

Benzinga

Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift

Medtronic plc (NYSE:MDT) announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately. This move comes shortly after Elliott Investment Management became the company’s largest shareholder.

Benzinga

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Eli Lilly And Co.‘s (NYSE:LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Therapeutics Inc. (NASDAQ:VKTX) emerging as a potential target.

Benzinga

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Ozempic sales surge ‘up to 600%’ after Mounjaro price rises

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to 'almost as good' competitor

Benzinga

Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

Shares of Dayforce Inc (NYSE:DAY) rose sharply in pre-market trading.

The Independent UK

Voices: Pricing people out of using Mounjaro would be bad news for the NHS

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous – impact on Britain’s pharmacies and patients, writes Leyla Hannbeck, CEO of the Independent Pharmacies Association

Benzinga

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).

Radio France Internationale

‘Close for a day so we don't close forever’: French pharmacies to go on strike

Pharmacists across France are staging a one-day protest on Saturday, warning that government cuts to generic drug discounts could spell the end for many of their businesses.

Evening Standard

Bioethanol plant deems lack of Government support an ‘act of economic self-harm’

Vivergo Fuels says it will have to close its Hull plant after the decision not to provide financial backing.

Benzinga

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) have rallied 30% over the past five sessions, though are marginally lower Thursday afternoon, as investors anticipate a key catalyst for the company.

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.